Ninlaro (ixazomib; Takeda) capsules are now available through an open distribution model that includes physician in-office dispensing and a specialty pharmacy network. Specialty pharmacies in the Ninlaro 1Point network include: Accredo, ACS/Omnicare Specialty Care Group, Avella, Axium, Biologics, Inc., CVS/specialty, Diplomat Pharmacy, US Bioservices, and Walgreens.
Ninlaro was approved in November 2015 for use in combination with lenalidomide (Revlimid; Celgene) and dexamethasone to treat patients with multiple myeloma who have received ≥1 prior therapy. Ninlaro is an oral proteasome inhibitor that works by blocking enzymes from multiple myeloma cells.
It was granted priority review and orphan drug designations by the FDA. Ninlaro is available as 2.3mg, 3mg, and 4mg strength capsules in single-capsule blister packs and 3-count cartons.
For more information call (844) 617-6468 or visit Ninlaro.com.